Cargando…

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors are a therapeutic milestone exerting a synthetic lethal effect in the treatment of cancer involving BRCA1/2 mutation. Theoretically, PARP inhibitors (PARPi) eliminate tumor cells by disrupting DNA damage repair through either PARylation or the homologou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Ye, Yu, Xiaopeng, Li, Shuqiang, Tian, Ye, Liu, Caigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724080/ https://www.ncbi.nlm.nih.gov/pubmed/33324554 http://dx.doi.org/10.3389/fonc.2020.578095

Ejemplares similares

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
por: Caputo, Roberta, et al.
Publicado: (2023)

NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer
por: Sonnessa, Margherita, et al.
Publicado: (2020)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
por: Zhu, Ying, et al.
Publicado: (2023)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
por: Schreier, Ashley, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
por: Zeng, Xiaoqi, et al.
Publicado: (2021)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
por: Shao, Nan, et al.
Publicado: (2019)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
por: Cañedo, Eduardo Cepeda, et al.
Publicado: (2021)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway
por: Wang, Kai-nan, et al.
Publicado: (2022)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_krbj23irm864e184oiog39bj81